Table 1:
Patient and treatment characteristics
| n=50 | % | |
|---|---|---|
| Age | ||
| <12 | 3 | 6% |
| 12–18 | 34 | 68% |
| 19–21 | 13 | 26% |
| Sex | ||
| Female | 27 | 54% |
| Male | 23 | 46% |
| Race/Ethnicity | ||
| Asian | 4 | 8% |
| Black | 9 | 18% |
| White | 30 | 60% |
| Hispanic | 3 | 6% |
| Multi-racial/Multi-ethnic | 2 | 4% |
| Other/Unknown | 2 | 4% |
| Stage | ||
| II | 23 | 46% |
| III | 13 | 26% |
| IV | 13 | 26% |
| Relapsed | 1 | 2% |
| Risk | ||
| Low | 3 | 6% |
| Intermediate | 19 | 38% |
| High | 28 | 56% |
| Bulky | ||
| Yes | 44 | 88% |
| No | 6 | 12% |
| B Symptoms | ||
| Yes | 26 | 52% |
| No | 23 | 46% |
| Unknown | 1 | 2% |
| Histologic subtype | ||
| Nodular sclerosing | 49 | 98% |
| Lymphocyte-predominant | 1 | 2% |
| Location | ||
| Mediastinum only | 7 | 14% |
| Non-mediastinum only | 1 | 2% |
| Both | 42 | 84% |
| Proton dose (Gy [RBE]) | ||
| 21–28 | 36 | 72% |
| 29–34 | 9 | 18% |
| 35–36 | 5 | 10% |
| Chemotherapy | ||
| ABVD | 15 | 30% |
| ABVE-PC | 34 | 68% |
| BEACOPP | 9 | 18% |
| Other | 7 | 14% |